CA2564399A1 - Use of equol for treating skin diseases - Google Patents
Use of equol for treating skin diseases Download PDFInfo
- Publication number
- CA2564399A1 CA2564399A1 CA002564399A CA2564399A CA2564399A1 CA 2564399 A1 CA2564399 A1 CA 2564399A1 CA 002564399 A CA002564399 A CA 002564399A CA 2564399 A CA2564399 A CA 2564399A CA 2564399 A1 CA2564399 A1 CA 2564399A1
- Authority
- CA
- Canada
- Prior art keywords
- equol
- skin
- administering
- androgen
- bind
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 title claims abstract 34
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 title claims abstract 31
- 235000019126 equol Nutrition 0.000 title claims abstract 30
- 208000017520 skin disease Diseases 0.000 title 1
- 239000003098 androgen Substances 0.000 claims abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 9
- 229940088597 hormone Drugs 0.000 claims abstract 8
- 239000005556 hormone Substances 0.000 claims abstract 8
- 102000001307 androgen receptors Human genes 0.000 claims abstract 7
- 108010080146 androgen receptors Proteins 0.000 claims abstract 7
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims abstract 6
- 201000010099 disease Diseases 0.000 claims abstract 5
- 230000001404 mediated effect Effects 0.000 claims abstract 5
- 210000004209 hair Anatomy 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 230000036541 health Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 20
- 210000003491 skin Anatomy 0.000 claims 20
- 230000009471 action Effects 0.000 claims 7
- 102000015694 estrogen receptors Human genes 0.000 claims 5
- 108010038795 estrogen receptors Proteins 0.000 claims 5
- 210000004761 scalp Anatomy 0.000 claims 5
- 230000007423 decrease Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- ADFCQWZHKCXPAJ-LBPRGKRZSA-N (R)-Equol Chemical compound C1=CC(O)=CC=C1[C@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-LBPRGKRZSA-N 0.000 claims 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 3
- 230000004963 pathophysiological condition Effects 0.000 claims 3
- 230000004962 physiological condition Effects 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 2
- 108010014258 Elastin Proteins 0.000 claims 2
- 206010068168 androgenetic alopecia Diseases 0.000 claims 2
- 210000000040 apocrine gland Anatomy 0.000 claims 2
- 230000036621 balding Effects 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 229920002549 elastin Polymers 0.000 claims 2
- 230000003779 hair growth Effects 0.000 claims 2
- 230000003646 hair health Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 206010067572 Oestrogenic effect Diseases 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 claims 1
- 206010039792 Seborrhoea Diseases 0.000 claims 1
- 206010040829 Skin discolouration Diseases 0.000 claims 1
- 108010085012 Steroid Receptors Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000037319 collagen production Effects 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 230000001076 estrogenic effect Effects 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 210000004013 groin Anatomy 0.000 claims 1
- 230000037308 hair color Effects 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 230000006872 improvement Effects 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000037312 oily skin Effects 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 210000001732 sebaceous gland Anatomy 0.000 claims 1
- 230000037075 skin appearance Effects 0.000 claims 1
- 230000037377 skin turgor Effects 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000003270 steroid hormone Substances 0.000 claims 1
- 102000005969 steroid hormone receptors Human genes 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 230000035900 sweating Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 abstract 2
- 229940030486 androgens Drugs 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000031018 biological processes and functions Effects 0.000 abstract 1
- 235000007240 daidzein Nutrition 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000035778 pathophysiological process Effects 0.000 abstract 1
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- 239000003075 phytoestrogen Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52145704P | 2004-04-28 | 2004-04-28 | |
| US60/521,457 | 2004-04-28 | ||
| PCT/US2005/004997 WO2005107770A1 (en) | 2004-04-28 | 2005-02-17 | Use of equol for treating skin diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2564399A1 true CA2564399A1 (en) | 2005-11-17 |
Family
ID=35320034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002564399A Abandoned CA2564399A1 (en) | 2004-04-28 | 2005-02-17 | Use of equol for treating skin diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050245492A1 (https=) |
| EP (2) | EP1740191A4 (https=) |
| JP (2) | JP5220406B2 (https=) |
| AU (1) | AU2005239984B2 (https=) |
| CA (1) | CA2564399A1 (https=) |
| WO (1) | WO2005107770A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2603479C2 (ru) * | 2010-05-28 | 2016-11-27 | М.Алфабет 1, ЛЛС. | Комбинированная терапия для кожных нарушений |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004039327A2 (en) * | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
| US8668914B2 (en) * | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| US20080108696A1 (en) | 2006-08-02 | 2008-05-08 | Brinton Roberta D | Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases |
| US8680140B2 (en) * | 2006-08-02 | 2014-03-25 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms |
| EP2063898A4 (en) | 2006-08-18 | 2012-02-15 | Univ Brigham Young | USE OF EQUOL TO IMPROVE OR PREVENT NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES OR DISORDERS |
| WO2008100560A2 (en) * | 2007-02-14 | 2008-08-21 | University Of Southern California | Estrogen receptor modulators, associated pharmaceutical compositions and methods of use |
| US8147759B2 (en) | 2007-08-29 | 2012-04-03 | Cem Corporation | Automated protein analyzer |
| US8852948B2 (en) * | 2007-08-29 | 2014-10-07 | Cem Corporation | Colorimetric protein analysis method |
| WO2009061832A1 (en) * | 2007-11-05 | 2009-05-14 | Kci Licensing Inc. | Identification of tissue for debridement |
| US20090222281A1 (en) * | 2008-03-03 | 2009-09-03 | Vibhuti Uppal | Formulation for multi-step acne treatment |
| US20110091435A1 (en) * | 2008-10-24 | 2011-04-21 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of hair loss |
| US20100247693A1 (en) * | 2009-03-24 | 2010-09-30 | Marini Jan L | Cosmetic formulation to treat rosacea telangiectasia |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| BR112012003804B1 (pt) | 2009-08-21 | 2019-02-19 | Novan, Inc. | Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento |
| MX339842B (es) | 2009-12-22 | 2016-06-14 | Avon Prod Inc | Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas. |
| US8591876B2 (en) * | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| CN102764253B (zh) * | 2012-07-16 | 2014-03-05 | 上海交通大学 | 苯并吡喃生物碱的应用 |
| JP2017531025A (ja) * | 2014-10-14 | 2017-10-19 | ジャクソン，リチャード・エル | Ｓ−エクオールの無水結晶形 |
| JP7068816B2 (ja) * | 2017-12-15 | 2022-05-17 | 大塚製薬株式会社 | エクオールおよびコラーゲンペプチドを含有する経口組成物 |
| AU2019285640A1 (en) | 2018-06-15 | 2021-01-21 | Board Of Regents Of The University Of Texas System | Methods of treating and preventing breast cancer with S-equol |
| JP2021535187A (ja) * | 2018-06-15 | 2021-12-16 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | Ｓ−エクオールを用いた黒色腫の処置及び予防方法 |
| JP7596493B1 (ja) * | 2023-11-24 | 2024-12-09 | 株式会社ダイセル | 男性のｑｏｌの改善のための組成物 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4390559A (en) * | 1979-04-11 | 1983-06-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
| US5468501A (en) | 1982-09-01 | 1995-11-21 | Hercon Laboratories Corporation | Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant |
| USRE34457E (en) * | 1983-12-28 | 1993-11-30 | Daicel Chemical Industries, Inc. | Separating agent |
| GB8626344D0 (en) * | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
| CH679584A5 (https=) * | 1989-11-10 | 1992-03-13 | Nestle Sa | |
| TW279133B (https=) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| EP0656786B2 (en) * | 1992-05-19 | 2014-04-23 | Novogen Research Pty Ltd | Use of isoflavone phyto-oestrogen extracts of soy or clover |
| US5436007A (en) | 1992-10-23 | 1995-07-25 | Abbott Laboratories | Diaper rash lotion |
| WO1994023716A1 (en) * | 1993-04-16 | 1994-10-27 | Tufts University School Of Medicine | Method for treatment of menopausal and premenstrual symptoms |
| US5613958A (en) | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
| US5320949A (en) * | 1993-10-12 | 1994-06-14 | Protein Technologies International, Inc. | Process for producing aglucone isoflavone enriched vegetable protein fiber |
| US5424331A (en) * | 1994-06-10 | 1995-06-13 | Bio-Virus Research Incorporated | Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis |
| US5523087A (en) * | 1995-02-15 | 1996-06-04 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction |
| AUPN166195A0 (en) * | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
| FR2731706B1 (fr) * | 1995-03-14 | 1997-04-11 | Cird Galderma | Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
| CN1188189C (zh) | 1995-06-07 | 2005-02-09 | 奥瑟－麦内尔制药公司 | 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途 |
| US5693018A (en) | 1995-10-11 | 1997-12-02 | Science Incorporated | Subdermal delivery device |
| US5821361A (en) * | 1996-06-11 | 1998-10-13 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
| AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| US5726034A (en) * | 1996-09-06 | 1998-03-10 | Protein Technologies International, Inc. | Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same |
| US6020471A (en) * | 1996-09-13 | 2000-02-01 | Abbott Laboratories | Process for isolating phytoestrogens from plant protein |
| US5804234A (en) * | 1996-09-13 | 1998-09-08 | Suh; John D. | Plant protein for nutritional products and method of making same |
| US5733926A (en) * | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
| AUPO427196A0 (en) * | 1996-12-19 | 1997-01-23 | University Of Sydney, The | A method for preventing or controlling cataract |
| US6146668A (en) * | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
| EP0979074A4 (en) * | 1997-05-01 | 2003-07-09 | Novogen Inc | TREATMENT OR PREVENTION CLIMATE ACTION SYMPTOMS AND OSTEOPOROSIS |
| US6083526A (en) * | 1997-05-22 | 2000-07-04 | Gorbach; Sherwood L. | Use of isoflavonoids in the treatment or prevention of postpartum depression |
| US6060070A (en) * | 1997-06-11 | 2000-05-09 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
| JP4310601B2 (ja) * | 1997-08-08 | 2009-08-12 | 大塚製薬株式会社 | イソフラボン含有組成物 |
| US6521433B1 (en) * | 1997-09-17 | 2003-02-18 | E. I. Du Pont De Nemours And Company | cDNA sequences from plants that encode activities associated with isoflavone biosynthesis |
| US5855892A (en) * | 1997-09-19 | 1999-01-05 | Potter; Susan M. | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease |
| US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
| US5942539A (en) * | 1997-10-03 | 1999-08-24 | Wake Forest University | Methods of treating or preventing endometriosis with phytoestrogens |
| AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
| US5958946A (en) * | 1998-01-20 | 1999-09-28 | Styczynski; Peter | Modulation of hair growth |
| US6004558A (en) * | 1998-02-25 | 1999-12-21 | Novogen, Inc. | Methods for treating cancer with legume plant extracts |
| AUPP260798A0 (en) * | 1998-03-26 | 1998-04-23 | Novogen Research Pty Ltd | Treatment of medical related conditions with isoflavone containing extracts of clover |
| EP1041964A4 (en) * | 1998-09-10 | 2003-09-03 | Avon Prod Inc | METHOD AND COMPOSITIONS FOR REDUCING DERMATOLOGICAL AGING AND FOR REDUCING CRUSHING |
| WO2000030664A1 (en) * | 1998-11-25 | 2000-06-02 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
| JP2002542187A (ja) * | 1999-04-16 | 2002-12-10 | アストラゼネカ・アクチエボラーグ | エストロゲン−β受容体リガンド |
| US6544566B1 (en) * | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| US6375994B1 (en) * | 1999-08-20 | 2002-04-23 | Sun Ten Laboratories, Inc. | Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| CA2416796A1 (en) * | 2000-06-14 | 2001-12-20 | Alla Shapiro | Radioprotective agents |
| US6455568B2 (en) * | 2000-07-06 | 2002-09-24 | Wyeth | Combination therapy for inhibiting sphincter incontinence |
| US6326366B1 (en) * | 2000-08-22 | 2001-12-04 | Protein Technologies International | Hormone replacement therapy |
| US6565864B2 (en) * | 2000-12-28 | 2003-05-20 | Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. | Skin care product containing retinoids and phytoestrogens in a dual compartment package |
| EP1234572B1 (de) * | 2001-02-26 | 2013-10-30 | Mibelle AG Cosmetics | Isoflavon-Aglykone enhaltende Hautbehandlungsmittel |
| MXPA03007609A (es) * | 2001-02-27 | 2004-06-30 | Univ Michigan | Uso de inhibidores egfr naturales para evitar efectos secundarios debidos a terapia de retinoide, jabones y otros estimulos que activan el receptor del factor de crecimiento epidermico. |
| DE10121375B4 (de) * | 2001-05-02 | 2014-01-16 | Beiersdorf Ag | Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut |
| FR2825277B1 (fr) * | 2001-05-30 | 2004-10-15 | Oreal | Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd |
| US6597597B2 (en) * | 2001-11-13 | 2003-07-22 | Hewlett-Packard Company | Low temperature attaching process for MRAM components |
| CN104643057A (zh) * | 2002-07-24 | 2015-05-27 | 儿童医院医疗中心 | 含有对映体牛尿酚的组合物和产物及其用途 |
| WO2004039327A2 (en) * | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
| EP1542654A4 (en) * | 2002-09-23 | 2008-12-17 | Novogen Res Pty Ltd | TREATMENT OF PHOTOTATIOOD AND ACTINIC DETERIORATION OF THE SKIN |
-
2005
- 2005-02-17 CA CA002564399A patent/CA2564399A1/en not_active Abandoned
- 2005-02-17 EP EP05723182A patent/EP1740191A4/en not_active Ceased
- 2005-02-17 AU AU2005239984A patent/AU2005239984B2/en not_active Ceased
- 2005-02-17 WO PCT/US2005/004997 patent/WO2005107770A1/en not_active Ceased
- 2005-02-17 US US11/059,951 patent/US20050245492A1/en not_active Abandoned
- 2005-02-17 JP JP2007510716A patent/JP5220406B2/ja not_active Expired - Lifetime
- 2005-02-17 EP EP10194495A patent/EP2305272A1/en not_active Withdrawn
-
2012
- 2012-10-04 JP JP2012222148A patent/JP2013006874A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2603479C2 (ru) * | 2010-05-28 | 2016-11-27 | М.Алфабет 1, ЛЛС. | Комбинированная терапия для кожных нарушений |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005239984B2 (en) | 2010-06-03 |
| JP2013006874A (ja) | 2013-01-10 |
| EP1740191A4 (en) | 2008-07-30 |
| EP1740191A1 (en) | 2007-01-10 |
| JP5220406B2 (ja) | 2013-06-26 |
| AU2005239984A1 (en) | 2005-11-17 |
| WO2005107770A1 (en) | 2005-11-17 |
| JP2007534751A (ja) | 2007-11-29 |
| EP2305272A1 (en) | 2011-04-06 |
| US20050245492A1 (en) | 2005-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2564399A1 (en) | Use of equol for treating skin diseases | |
| Muallem et al. | Physiological and biological skin changes in pregnancy | |
| US20100029784A1 (en) | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties | |
| US20100010100A1 (en) | Dermatological compositions with anti-aging and skin even-toning properties | |
| JP2007534751A5 (https=) | ||
| CN114948773A (zh) | 一种护肤品组合物及其制备方法与用途 | |
| US9554985B2 (en) | Agent for promoting hair growth and method for preparing same | |
| JP2006508942A5 (https=) | ||
| JP2018502116A (ja) | Ｒｇｄモチーフ含有ペプチドまたはその断片を含む火傷及び緑内障治療、皮膚のしわ改善及び発毛促進用の組成物 | |
| Parmley et al. | Skin changes during pregnancy | |
| Draelos et al. | A pilot study evaluating the anti‐aging benefits of a CO2‐emitting facial mask | |
| CN104825347B (zh) | 一种医用生物美白袪斑敷料及其制备方法 | |
| WO2011085013A2 (en) | Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same | |
| KR20150115186A (ko) | 올리브잎 추출물을 포함하는 튼살 완화용 화장료 조성물 | |
| Geetha | Skin and Menopause | |
| JP7591492B2 (ja) | ヘアケアの分野において使用するためのレスペデザ・カピタータ抽出物 | |
| WO2011141611A1 (es) | Composiciones de oleuropeína para cicatrización de heridas y úlceras en ancianos y/o diabéticos | |
| JPS6011884B2 (ja) | 毛髪及び皮膚手入用化粧料 | |
| JPH0112725B2 (https=) | ||
| Draelos et al. | A pilot study evaluating the anti-aging benefits of a CO | |
| Cao | GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions | |
| Tenenbaum et al. | Cosmetic Dermatology | |
| Suresh et al. | Androgenic alopecia: Recent understanding of the androgenetic receptor-mediated molecular mechanisms and current pharmacotherapy | |
| Warowna et al. | Physiological dermatological changes in women’s female and skin care in a beauty salon | |
| Bechtel | Physiologic skin changes in pregnancy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130326 |